ACE-031 vs Oxandrolone
Emerging vs Well Studied
monitor Mechanism-based · 46% Both ACE-031 and Oxandrolone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone.
Molecular Data
ACE-031 Oxandrolone
Weight — 306.44 Da
Half-life 12-15 days ~9-10 hours
Type Soluble activin receptor type IIB-Fc fusion protein 17-alpha-alkylated anabolic-androgenic steroid (C19H30O3)
Key Benefits
ACE-031
01 Significant lean mass increases (up to 1.7% in 29 days) observed in Phase 1 trials
02 Simultaneous reduction in fat mass alongside muscle gains
03 Long half-life (12-15 days) allows infrequent dosing
04 Broad TGF-beta ligand neutralization for robust anti-catabolic effects
05 Dose-dependent increases in thigh muscle volume confirmed by MRI
Oxandrolone
01 Promotes lean muscle mass gains with minimal water retention
02 Supports recovery of lost body weight following surgery, trauma, or chronic illness
03 Reduces bone pain associated with osteoporosis and improves bone mineral density
04 Does not aromatize to estrogen, avoiding estrogen-related side effects
05 Well-studied safety profile in women, children, and burn patients
06 Enhances nitrogen retention and protein synthesis during caloric deficit
07 Attenuates glucocorticoid-induced catabolism in post-surgical and burn patients
08 Lower androgenic potency compared to most oral anabolic steroids
Dosing Protocols
ACE-031
0.5-3 mg/kg IV every 2 weeks (clinical research doses only) / Every 2 weeks
Phase 1 Research Protocol (Healthy Volunteers) 0.1-3 mg/kg Single IV dose
Phase 2 Research Protocol (DMD) 0.5-2.5 mg/kg Every 2 weeks
Oxandrolone
20-50 mg/day (male), 5-20 mg/day (female) / Split into 2 doses daily (morning and evening)
Side Effects
ACE-031
Nosebleeds (epistaxis) - most frequently reported adverse event
Gum bleeding
Telangiectasia (dilated small blood vessels visible on skin)
Skin erythema (redness)
Minor injection site reactions
Oxandrolone
HDL cholesterol suppression (dose-dependent, most significant lipid effect)
LDL cholesterol elevation
Mild hepatic stress (elevated liver enzymes ALT/AST)
Suppression of endogenous testosterone production
Mild headaches
Nausea or gastrointestinal discomfort
Changes in libido (increase or decrease depending on hormonal context)
Oily skin and mild acne
Contraindications
NEVER approved for human use - clinical development discontinued
History of bleeding disorders or vascular malformations
Concurrent anticoagulant or antiplatelet therapy
Known hypersensitivity to Fc fusion proteins
Pregnancy or breastfeeding
Known or suspected prostate cancer
Breast cancer in males
Breast cancer with hypercalcemia in females
Pregnancy (Category X - known to cause fetal harm)
Nephrosis or nephrotic phase of nephritis
Hypercalcemia
Severe hepatic dysfunction or active liver disease
Hypersensitivity to oxandrolone or any formulation component
Research Evidence
ACE-031 Oxandrolone
Status Emerging Well Studied
References 4 studies 5 studies
Latest — September 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.